Intensely potent doxorubicin analogues: structure-activity relationship

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Discovery

Background:

• N-(5,5-Diacetoxypent-1-yl)doxorubicin (1b) is a cytotoxic doxorubicin analogue.
• It retains potency against P-glycoprotein-overexpressing, doxorubicin-resistant tumor cells.
• 1b is designed for esterase-mediated hydrolysis to an aldehyde intermediate.

Purpose of the Study:

• To investigate the structural determinants of N-(5,5-Diacetoxypent-1-yl)doxorubicin (1b) potency.
• To assess the impact of chain length, oxygen substitution, and carbinolamine ring size on analogue activity.
• To evaluate novel doxorubicin analogues against various cancer cell lines.

Main Methods:

• Synthesis of chemically related doxorubicin analogues with varied omega-[bis(acetoxy)]alkyl or omega-[bis(acetoxy)]alkoxyalkyl groups at the 3'-amino position.
• In vitro growth inhibition assays using Chinese hamster ovary (CHO) cells, a multidrug-resistant CHO mutant, Panc 02, and CA 755 cell lines.
• Structure-activity relationship analysis based on esterase hydrolysis products and carbinolamine ring formation.

Main Results:

• Optimal potency was observed for analogues forming 5- or 6-membered carbinolamines after hydrolysis.
• Analogues forming larger carbinolamine rings (7-, 8-, or 9-membered) exhibited significantly reduced activity.
• A non-cyclic carbinolamine-forming N-methyl derivative and a branched analogue showed markedly lower potency compared to 1b.

Conclusions:

• The chain length of 3'-amino substituents is a critical determinant of doxorubicin analogue biologic potency.
• The ability of derived aldehydes to form 5- or 6-membered cyclic carbinolamines is essential for high activity.
• These findings provide insights for designing novel doxorubicin analogues targeting multidrug-resistant cancers.